Access to data: EMA in key position.
ثبت نشده
چکیده
The European Medicines Agency must fulfil its transparency obligations and resist industry pressure.
منابع مشابه
Network Analysis of Interpersonal Relationships in Tehran Stock Exchange
The stock market has an important role in growth and development of countries. Network analysis is one of the latest method in analyzing the stock market. In quantitative science literature, It is a new concept for a macro view to whole market. Therefore, this research analyzes the interpersonal relationships’ network in the Tehran Stock Exchange (TSE). From the type of data collected and analy...
متن کاملHow do we avoid disaster when exiting the European Medicines Agency? Making the most of Brexit in pharmaceutical regulation
As the UK prepares to leave the EU, it must decide what path it is to take with a large number of regulatory and technical agencies who provide collaboration at the European level. In the case of pharmaceuticals, the European Medicines Agency (EMA) provides pan-European licencing for novel pharmaceuticals. Should the UK depart from the EMA system, this article highlights the loss to patients im...
متن کاملInterpolation of tongue fleshpoint kinematics from combined EMA position and orientation data
Articulatory data such as that collected via electromagnetic articulography (EMA) are valuable for many speech applications, including speech modeling, recognition, and synthesis. Nearly all current EMA applications and methods focus on the use of positional sensor data, even though modern 3D-EMA systems also capture sensor orientation, which provides significant additional information about ar...
متن کاملAccess to regulatory data from the European Medicines Agency: the times they are a-changing
Systematic reviewers are increasingly trying to obtain regulatory clinical study reports (CSRs) to correct for publication bias. For instance, our organization, the Institute for Quality and Efficiency in Health Care, routinely asks drug manufacturers to provide full CSRs of studies considered in health technology assessments. However, since cooperation is voluntary, CSRs are available only for...
متن کاملOutcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia
Background: Gestational trophoblastic neoplasia (GTN) originates from placental trophoblast and is a highly chemosensitive and curable gynecologic malignancy. The present study was conducted to evaluate the effectiveness and safety of EMA/EP (etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin) regimen in the treatment of high-risk GTN as well as patients’ outcome. &nb...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Prescrire international
دوره 24 160 شماره
صفحات -
تاریخ انتشار 2015